New joint venture to drive development of Oxford North

Following on from the recent establishment of a new board, Thomas White Oxford, the development company of St John’s College Oxford, has agreed a 50:50 joint venture partnership with Canadian-based Cadillac Fairview, the real estate arm of Ontario Teachers’ Pension Plan, with developer Stanhope PLC, to deliver Oxford North, the new £700 million innovation district in the City of Oxford.

A new company, Oxford North Ventures LLP, has been formed as a JV, 50% owned by Thomas White Oxford and 50% by Canadian-based Cadillac Fairview and developer Stanhope. Stanhope has also been appointed as development manager.

The joint venture will invest almost £700 million to deliver 939,000 sq ft (87,300 sq m) of laboratory and workspace to enable life-enhancing discovery, along with amenities, infrastructure and social value during the next several years.

In March 2021, outline consent was granted by Oxford City Council for the overall 64-acre masterplan and detailed consent for the first phase of new laboratories and workspace, which will total 170,000 sq ft (15,793 sq m), with a link road and Central Park.  Enabling infrastructure works started in August 2021. Future labs and workspace phases across Central and Eastside will be delivered by the joint venture.

For further information, view the full news story here: https://www.oxfordnorth.com/news/thomas-white-oxford-agrees-joint-venture-with-cadillac-fairview-and-stanhope-to-deliver-oxford-north/

Recent news

Sauber Motorsport opens Technology Centre at Bicester Motion

Sauber Motorsport opens Technology Centre at Bicester Motion

Sauber Motorsport has opened its new Technology Centre at Bicester Motion. The primary purpose of the facility at the 444-acre future mobility estate is to enhance and expand the team’s technical capabilities, to ensure the team is well-positioned to attract top...

read more
Immunocore Wins Prix Galien UK Award for KIMMTRAK

Immunocore Wins Prix Galien UK Award for KIMMTRAK

Immunocore has been awarded a Prix Galien UK award for KIMMTRAK, its treatment for metastatic uveal melanoma- a rare and aggressive form of eye cancer. The Prix Galien UK is one of the highest accolades in the life sciences sector, recognising outstanding innovation...

read more
Business and Trade Committee Launches Two Important Inquiries

Business and Trade Committee Launches Two Important Inquiries

The UK’s Business and Trade Committee has recently announced the launch of two significant inquiries- both of which present crucial opportunities for stakeholders across business, research, and innovation sectors to have their voices heard at a national level. UK...

read more
Loading...